biostudies-literatureRuggenenti PAgenzia Italiana del Farmaco, Ministero della Salute575-587https://www.ebi.ac.uk/biostudies/studies/S-EPMC8092055biostudies-literatureUnknown16(4)<h4>Background and objectives</h4>Renin-angiotensin system (RAS) inhibitors reduce cardiovascular morbidity and mortality in patients with CKD. We evaluated the cardioprotective effects of the angiotensin-converting enzyme inhibitor ramipril in patients on maintenance hemodialysis.<h4>Design, setting, participants, & measurements</h4>In this phase 3, prospective, randomized, open-label, blinded end point, parallel, multicenter trial, we recruited patients on maintenance hemodialysis with hypertension and/or left ventricular hypertrophy from 28 Italian centers. Between July 2009 and February 2014, 140 participants were randomized to ramipril (1.25-10 mg/d) and 129 participants were allocated to non-RAS inhibition therapy, both titrated up to the maximally tolerated dose to achieve predefineClinical journal of the American Society of Nephrology : CJASNRamipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis: The ARCADIA Multicenter Randomized Controlled Trial.PMC8092055FARM 6WE4PPCorghi EPozzi CRota SBarbisoni FMartina VSassone DGranata ATamburello SGidaro BBini SAnders HJMambelli ESalamone BInguaggiato PRuggenenti PGuastoni CMCasiraghi ESantorelli GBadalamenti SMeterangelis AFarina MFabbrini PGenovesi SPani APedone MARCADIA Study OrganizationRiva MALonghena GRCortinovis EScanziani RValentino RSestigiani EBigatti GDiadei OCortinovis MBattaglia GGCantarelli CPasquali SCozzolino MPieruzzi FBellotti NBovino AScolari FRigotti AGiuliano GAOttaviano GPodesta MAGalfre ASpotti DPorrini EStefani FBlanco VCerretani DRubis NNeri ALTedoldi SBoccardo PPeracchi TPeracchi SZambianchi LStasi ACarminati SPerna AMingardi GRemuzzi GLedda GFConte FDavid SMosconi GBolasco PCalini WSabadini ETeatini UMurtas SDessi GVilla AGarozzo MMartinetti DOndei PMalandra RStella APersici EBertoli SVPeraro FPacitti ATrillini MDel Rosso GDaidone GRomei Longhena GHidalgo Godoy JAlibrandi MTSVilla DCondemi CGBove SMancini EfalseRamipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis: The ARCADIA Multicenter Randomized Controlled Trial.<h4>Background and objectives</h4>Renin-angiotensin system (RAS) inhibitors reduce cardiovascular morbidity and mortality in patients with CKD. We evaluated the cardioprotective effects of the angiotensin-converting enzyme inhibitor ramipril in patients on maintenance hemodialysis.<h4>Design, setting, participants, & measurements</h4>In this phase 3, prospective, randomized, open-label, blinded end point, parallel, multicenter trial, we recruited patients on maintenance hemodialysis with hypertension and/or left ventricular hypertrophy from 28 Italian centers. Between July 2009 and February 2014, 140 participants were randomized to ramipril (1.25-10 mg/d) and 129 participants were allocated to non-RAS inhibition therapy, both titrated up to the maximally tolerated dose to achieve predefine2021-01-01T00:00:00Z2021 Apr2026-05-08T10:41:47.724Z2025-04-04T10:17:19.682ZS-EPMC80920553378203610.2215/CJN.1294082010.2215/cjn.12940820